Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer

• Principais autores: Boxue Ren (Autor), Lei Ye (Autor), Jianwei Gong (Autor), Huanhuan Ren (Autor), Yangfang Ding (Autor), Xiaoyu Chen (Autor), Xiaona Liu (Autor), Peng Lu (Autor), Fei Wei (Autor), Wenjuan Xu (Autor), Qiusheng Zheng (Autor), Defang Li (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2019-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The first-line chemotherapy drug adriamycin (ADM) is widely used for the treatment of breast cancer, but the acquired drug resistance and the normal tissue toxicity remain clinical challenges. Alteronol has been reported to exert wide-ranging anti-tumor activity. In this study, we firstly examined t...